• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SVP and Chief Legal Officer Tandy Bradley J was granted 13,275 shares, increasing direct ownership by 49% to 40,315 units (SEC Form 4)

    3/11/25 9:00:02 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tandy Bradley J

    (Last) (First) (Middle)
    2711 CENTERVILLE ROAD
    SUITE 400

    (Street)
    WILMINGTON DE 19808

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Enovis CORP [ ENOV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP and Chief Legal Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock, par value $0.001 03/07/2025 A 13,275(1) A $0 40,315 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This award represents restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.
    /s/ Brian P. Hanigan, attorney-in-fact 03/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ENOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Financials

    Live finance-specific insights

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Fourth Quarter and Full Year 2024 Results

      Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F

      2/26/25 6:01:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enovis Corporation

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      11/14/24 1:28:31 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      4/5/24 12:21:51 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      2/14/24 10:04:36 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shirley Brady was granted 829 shares, increasing direct ownership by 0.84% to 99,196 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      4/11/25 9:30:04 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Director Lalor Angela S was granted 589 shares, increasing direct ownership by 5% to 13,237 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      4/1/25 9:00:07 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SVP, Chief Financial Officer Berry Phillip Benjamin (Ben) was granted 24,137 shares, increasing direct ownership by 76% to 55,983 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      3/11/25 9:00:16 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

      NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

      1/7/25 6:19:00 PM ET
      $ARCH
      $CART
      $CEIX
      $ENOV
      Coal Mining
      Energy
      Business Services
      Consumer Discretionary
    • Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

      WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

      9/9/24 3:50:00 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Enovis Corporation

      10-Q - Enovis CORP (0001420800) (Filer)

      5/8/25 5:14:27 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enovis CORP (0001420800) (Filer)

      5/8/25 6:19:47 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by Enovis Corporation

      DEF 14A - Enovis CORP (0001420800) (Filer)

      4/11/25 4:01:52 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Enovis Corporation with a new price target

      JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

      10/3/24 7:29:21 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Enovis Corporation with a new price target

      JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

      6/13/24 7:06:52 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Stephens initiated coverage on Enovis Corporation with a new price target

      Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

      2/13/24 6:34:49 AM ET
      $ENOV
      Industrial Specialties
      Health Care